BMY Stock Analysis: Buy, Sell, or Hold?
BMY - Bristol-Myers Squibb Co.
$58.13
1.69 (2.99%)
▲
5d:
+4.95%
30d:
+6.74%
90d:
-5.83%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 30, 2026
26d
Smart Money Distribution
None View Scanner →
Strength: 9.0/10
Get Alerted When BMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called BMY this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: BMY is fairly valued with market pricing in 0.3% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: BMY is fairly valued with market pricing in 0.3% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.75
Based on 0.9% avg growth
INTRINSIC VALUE TODAY
$37.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMY is currently trading at $58.13, which is considered extended relative to its 30-day fair value range of $55.06 to $57.51. The stock's valuation (Forward PE: 9.4) is in line with its historical norms (9.3). At these levels, the market is pricing in 0.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BMY is in a strong downtrend. The price is approaching resistance at $58.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, BMY is in a strong downtrend. The price is approaching resistance at $58.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BMY has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$55.06 -
$57.51
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
58.1%
Protect Your Profits
Holding BMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($63.08)
- NEUTRAL: Market pricing in 0.3% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$55.06 -
$57.51
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$53.44
Resistance Level
$58.88
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.43
Wall Street Target
$63.08
(+8.5%)
Revenue Growth (YoY)
2.6%
Earnings Growth (YoY)
9.2%
Profit Margin
15.0%
Valuation Premium vs History
+0.3% premium
PE vs Historical
9.4 vs 9.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.3%
(market-implied from PE analysis)
1-Year Target
$58.30
(+0%)
2-Year Target
$58.48
(+1%)
3-Year Target
$58.65
(+1%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
PE COMPRESSION
$57.86
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -2.3%)
$125.30
(+116%)
Base:
(SPY PE: 9.4, Growth: -2.3%)
$54.24
(-7%)
Bear:
(PE: 8.0, Growth: -2.3%)
$46.10
(-21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 15.81 | Current EPS (TTM): $3.57
Bull Case
$107.23
(+85%)
Analyst growth 72.7%, PE expands to 17.4
Base Case
$97.48
(+68%)
Market implied 72.7%, PE stable at 15.8
Bear Case
$38.38
(-34%)
Severe decline -20.0%, PE contracts to 13.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 03, 2026 6:23 PM ET
Data refreshes hourly during market hours. Next update: 7:23 PM
Data refreshes hourly during market hours. Next update: 7:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMY showing a specific setup today?
Insider Activity (6 Months)
2
Buys
2
Sells
0
Net
INSIDERS SELLING
Recent Transactions
David V Elkins
SELL
30000 shares
2026-04-01
Ro Khanna
BUY
2026-02-05
Ro Khanna
SELL
2026-01-29
Featured in Portfolios
BMY is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1223 | 61 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 69 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 67 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 60 HOLD |
Advanced BMY Option Strategies
Professional options setups generated by AI based on today's BMY price and gamma walls.
